Stone William M, Naidu Sailendra G, Chapital Alyssa, Money Samuel R
Department of Surgery, Mayo Clinic, Phoenix, AZ 85054, USA.
Ann Vasc Surg. 2010 Jan;24(1):140-8. doi: 10.1016/j.avsg.2009.03.008. Epub 2009 Jul 19.
Antiplatelet medications have been proven to enhance outcomes in patients with cardiovascular disease. The ideal platelet inhibitor would be quick and reversible and would have universal response, an excellent safety profile, and proven benefit. Currently available antiplatelet medications have been demonstrated to have variable patient response. In light of this medication resistance, emerging therapies to inhibit platelet aggregation are under investigation. We review the currently available antiplatelet medications and the current state of these emerging therapies.
抗血小板药物已被证明可改善心血管疾病患者的预后。理想的血小板抑制剂应起效迅速且作用可逆，具有普遍的反应性、出色的安全性及已证实的疗效。目前可用的抗血小板药物已显示出患者反应存在差异。鉴于这种药物抵抗性，抑制血小板聚集的新兴疗法正在研究中。我们综述了目前可用的抗血小板药物以及这些新兴疗法的现状。
